Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

Meeting

Biomedical meeting

American Heart Association (AHA)

Heart / cardiovascular diseases

November 7-10, 2025

AHA 2025 Meeting dates: Nov 7-10, 2025.

Meeting dates

Meeting

Biomedical meeting

AASLD The Liver Meeting

Liver disease

November 7-11 2025

The Liver Meeting dates: Nov 7-11, 2025.

Meeting dates

ARWR

PDUFA

Plozasiran (ARO-APOC3)

FCS (Familial Chylomicronemia Syndrome)

Nov 18, 2025

PALISADE trial. 6/3/24- Topline data at cardiometabolic webinar. 9/2/24- Results reported at ESC 2024. 9/10/24- FDA granted BTD. 11/18/24- New data presented at AHA24. NDA submitted. 1/17/25- NDA accepted with PDUFA action date of Nov 18, 2025.

Approval decision

Meeting

Biomedical meeting

The Clinical Trials on Alzheimer's Disease (CTAD)

Alzheimer's disease

December 1-4, 2025

CTAD 2025: Meeting dates Dec 1-4, 2025 in San Diego, California

Meeting dates

ASMB

Phase 1b

ABI-5366

Genital Herpes (HSV)

Fall 2025

8/8/24- Initiated dosing of healthy subjects. 9/23/24- Positive Interim Ph1a data. 2/20/25- Ph1b ongoing. 3/20/25- Interim PoC data in Fall 2025.

Data readout

ASMB

Phase 1b

ABI-1179

Recurrent genital herpes (HSV)

Fall 2025

2/20/25- Reported interim Ph1a results. 3/20/25- Interim efficacy, safety and PK data in fall 2025.

Data readout

CORT

PDUFA

Korlym® (Relacorilant)

Hypercortisolism (Cushing Syndrome)

December 30, 2025

GRACE trial. Completed Ph3 Enrollment. 4/22/24- Reported positive OLE results. 5/28/24- Met primary endpoint. 6/3/24 Present add'l data at ENDO '24 & at HiD on June 7th. NDA submission by Q4 2024. Ph3 OLE results presented at WCIRDC. 12/30/24- NDA submitted. 3/3/25- NDA accepted. PDUFA target action date December 30, 2025.

Approval decision

SWTX

Phase 1a/1b

Brimarafenib (BGB-3245)

Solid tumors-RAF mutant

H2 2025

Collab w/ BeiGene. 2/29/24 Ongoing Ph1b dose expansion & additional data in H2 2025.

Data Readout

ARGX

Phase 2

Empasiprubart

Delayed graft function (DGF)

H2 2025

Initiation by YE 2023. 2/27/25- Topline data expected expected H2 2025

Data readout

INSM

Phase 2

Brensocatib (DPP1 inhibitor)

CRSsNP (Chronic rhinosinusitis w/o nasal polyps)

YE 2025

BiRCh trial. Initiates Ph2 study in Q4 2023. 2/22/24 Currently enrolling. 2/20/25 Topline data in YE 2025

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20